Open Access Published since March 20, 2021

Frigid Zone Medicine

ISSN: 2719-8073

Submit manuscript

About this journal

Frigid Zone Medicine, a high-quality, open access, medical journal in the English language, starts the first issue in 2021. The journal is managed by the Heilongjiang Health Commission and organized by the Heilongjiang Health Development Research Center.

This journal publishes articles on the latest research results and leading developments in the field of Frigid Zone medicine, providing an international academic platform for local and overseas researchers of the related field. The journal aspires to increase the quality of regional and national health research. It aims at building a qualified international medical platform for academic communication and development, leading the academic studies and practices, promoting the international clinical researches and experiments of Frigid Zone, and improving the academic impact in this field.

According to the latest research, Frigid Zone Medicine defines the field of Frigid Zone as the regions with an average temperature below 0℃ in the winter. In the definition, many parts of the world are covered as places with cold weather. The journal is willing to explore the health-related research and reports in regions with cold weather, aiming at recognizing and exploring the health-related problems in regions with cold weather, encouraging more research on the treatment of diseases caused by cold weather, promoting the health development and communication on the health-related research of the cold regions, and advocating the health-related quality of residents in these areas. Frigid Zone Medicine keeps health care professionals at the leading edge of medical knowledge, helps them to gain broad understanding in their areas of interest, and provides a variety of engaging and innovative ways to communicate.

The editorial committees are selected from an international pool of researchers with high levels of achievement and recognition in their fields, having stellar reputations in their disciplines. The editorial committee of this journal comprises of scientists from across the world.

The mission of Frigid Zone Medicine is to provide fair, fast, and expert peer review to authors and a vetted selection of research, freely available to readers. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other’s identity. The journal fosters the advance of the clinical practice and health research. The column consists of disease study, academic communication, expert forum, international dynamics and references. The scope of the journal encompasses international medical specialists’ reviews, clinical guidance, clinical commentaries, special comments, clinical reports, research reports, case study reports, short communications, correspondence and technical progress, etc.

Frigid Zone Medicine welcomes submissions from all fields of health and from any source. The journal invites submissions on topics pertaining to health-related research in cold regions, including but not limited to non-communicable diseases, internal medicine, basic medical science, mental disease, cardiology, rheumatology, pneumology, angiology, altitude stress, frostbite, aging health, and health policy.

Aiming at high-level international journals, Frigid Zone Medicine strictly complies with the international disciplines and strategies of the editing and publication. It closely follows the industry associations. The journal is committed to meeting and upholding standards of ethical behavior at all stages of the publication process. It follows the peer-review process, and the reviewers are internationally renowned experts. It provides editorial, peer, and statistical review processes to evaluate manuscripts for scientific accuracy, novelty, and importance.

Frigid Zone Medicine is published internationally, and all articles published in this journal are made freely and permanently accessible online. Frigid Zone Medicine is a quarterly journal, with 64 pages and color cover. It covers subjects of basic medical science and clinical medicine. The publications, in print and online, reach a truly worldwide audience. Editorial Manager, Online Publishing Platform, and Advance Online Publication (AOP) are applied. Research in our journals is given extra accessibility and depth through commentaries, reviews, and editorial summaries.

Frigid Zone Medicine will start publication in 2020. At the beginning of the development, it has received the project of “High Beginning New Journal” supported by the China Association for Science and Technology. This journal is managed by a research center with a long history of managing a group of journals in varied medical fields. The facilitated research center has appropriative cooperation, which has well reputation and basement in developing journals, providing excellent publishing resources.

Frigid Zone Medicine invites contributions all over the world.

Abstracting and Indexing

Frigid Zone Medicine is covered by the following services:

Baidu Scholar
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO Discovery Service
Google Scholar
J-Gate
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
ReadCube
Scilit
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

Topics

External Links

Online Submission of Manuscripts

Volume 4 Issue 1

March 2024

Special Study

Open Access April 30, 2024

The link between dietary nutrients intake and cardiovascular diseases in cold regions

Rennan Feng, Qianqi Hong, Jingjing Cao, Jian Li, Lanxin Deng, Jing Wang, Yang Zhao, Cheng Wang

Page range: 1-11

More Download PDF

Abstract

Background The cold winter weather in northern China influences the dietary habits of its residents, contributing to a heightened risk of cardiovascular disorders, such as hypertension and coronary heart disease. Key factors include low vegetable consumption and high salt and fat intakes. This study aims to investigate the relationships between northern dietary nutrient intake in northern China and cardiovascular disorders during the winter season. Methods A food frequency questionnaire tailored to the actual eating habits in northern China was designed. Retrospective data from 955 Chinese adults were collected from November to March between 2014 to 2023. Logistic regression was employed to analyze the relationship between dietary nutrients and cardiovascular diseases, with model performance assessed using receiver operating characteristic (ROC) curves. Results Adjusted for gender, age, and body mass index (BMI), an inverse association was observed between vitamin A ( OR = 0.706, 95% CI: 0.550, 0.907), nicotinic acid ( OR = 0.584, 95% CI: 0.447, 0.762), phosphorus ( OR = 0.777, 95% CI: 0.608, 0.994), selenium ( OR = 0.719, 95% CI: 0.560, 0.923), zinc ( OR = 0.683, 95% CI: 0.531, 0.880), methionine ( OR = 0.730, 95% CI: 0.569, 0.936), arginine ( OR = 0.753, 95% CI: 0.588, 0.964), lysine ( OR = 0.706, 95% CI: 0.550, 0.907), aspartic acid ( OR = 0.730, 95% CI: 0.569, 0.936) and hypertension. Additionally, a negative association was found between niacin ( OR = 0.752, 95% CI: 0.597, 0.946) and coronary heart disease. Conversely, a positive association was identified between iodine and hypertension ( OR = 1.305, 95% CI: 1.020, 1.669) and coronary heart disease ( OR = 1.301, 95% CI: 1.037, 1.634). Conclusion Our study suggests that maintaining a balanced dietary intake of vitamin A, niacin, phosphorus, selenium, zinc, methionine, arginine, lysine, and aspartic acid can be beneficial in preventing hypertension. Adequate niacin intake is associated with a lower risk of coronary heart disease. However, excessive iodine intake may contribute to hypertension and coronary heart disease.

Original Article

Open Access April 30, 2024

Peroxisome proliferator-activated receptors gama ameliorates liver fibrosis in non-alcoholic fatty liver disease by inhibiting TGF-β/Smad signaling activation

Qingwei Zhang, Wenjie Zhao, Zeqi Sun, Xinxin Dong, Liwei Zhu, Zhen Zhang, Ximing Chen, Yingying Hu, Menghan Du, Jiamin Li, Yong Zhang

Page range: 12-22

More Download PDF

Abstract

Background Nonalcoholic fatty liver disease (NAFLD) is a chronic condition characterized by a progressive decline in liver function, leading to disruptions in liver integrity and metabolic function, resulting in lipid deposition and excessive accumulation of extracellular matrix (ECM). The pathogenesis of NAFLD is complex and not yet fully understood, contributing to the absence of specific therapeutic strategies. Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor pivotal in regulating lipid and glucose metabolism. However, the impacts of PPARγ on NAFLD remains insufficiently explored. Thus, this study aimed to investigate the role of PPARγ in NAFLD and its underlying molecular mechanisms. Methods Chemical detection kits were utilized to quantify collagen content, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) level variations. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to assess alterations in extracellular matrix-related genes and inflammatory response genes in liver tissue and HepG2 cells, while western blotting was conducted to analyze the levels of both PPARγ and the TGF-β/Smad signaling pathway. Results Our findings unveiled significantly reduced PPARγ expression in a rat model of NAFLD, leading to subsequent activation of the TGF-β/Smad signaling pathway. Furthermore, PPARγ activation effectively mitigated NAFLD progression by inhibiting inflammation and fibrosis-related gene expression and collagen production. On a cellular level, PPARγ activation was found to inhibit the expression of extracellular matrix-related genes such as matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), along with inflammatory response genes interleukin (IL)-1β and IL-6. Additionally, PPARγ activation led to a significant decrease in the levels of ALT and AST. At the molecular level, PPARγ notably down-regulated the TGF-β/Smad signaling pathway, which is known to promote liver fibrosis. Conclusion These groundbreaking findings underscore PPARγ activation as a promising therapeutic approach to delay NAFLD progression by targeting the TGF-β/Smad signaling pathway in hepatic cells. This highlights the potential of PPARγ as a promising therapeutic target for NAFLD management in clinical settings.

Open Access April 30, 2024

Clinical characteristics and north-south differences of inflammatory bowel disease in China: A cross-sectional study and meta-analysis

Qi Liang, Bo Qu, Chunye Li, Yue Hu, Chunyi Yang, Tingting Yang, Yuzhu Di, Hui Li

Page range: 23-30

More Download PDF

Abstract

Objective This study aimed to estimate the incidence rate and clinical characteristics of inflammatory bowel disease (IBD) in the Chinese population, specially comparing the North and South regions. Methods We designed a questionnaire survey for patients diagnosed with IBD and conducted a systematic literature search in PubMed, China National Knowledge Internet, and Wanfang digital database, covering studies published between 2012 and 2022. Meta-analysis was performed to determine the overall incidence rate and prevalence of clinical manifestations of Crohn’s disease (CD) and ulcerative colitis (UC) in mainland China. Clinical phenotypes and demographic characteristics were calculated with 95% confidence intervals (CI). A comparison between the northern and southern regions was also conducted. Results The questionnaire survey included 440 patients, and 64 publications were included for Meta-analysis. The overall incidence rates of IBD, CD, and UC were 1.36 (95% CI: 0.79-2.33) per 100,000 person-years, 0.23 (95% CI: 0.09-0.58) per 100,000 person-years, and 1.12 (95% CI: 0.69-1.80) per 100,000 person-years, respectively. The incidence rates of IBD, CD, and UC were all higher in southern China compared to the North. Clinical characteristics of 440 IBD patients from the questionnaire and 2,821 CD patients and 12,809 UC patients from the literature were analyzed. There were more male patients compared to female patients. CD cases in the North exhibited earlier disease diagnosis ( P < 0.01), more upper gastrointestinal lesions ( P < 0.01), and higher hospitalizations rates ( P < 0.01) compared to the South. UC cases in the North had higher severity ( P < 0.01), anemia rates ( P < 0.01), and weight loss ( P < 0.01) compared to the South. Conclusions The incidence rates of IBD, CD, and UC were higher in southern China than in the North. Northern patients exhibited more severe symptoms compared to their southern counterparts.

Open Access April 30, 2024

Long non-coding RNA-AK138945 regulates myocardial ischemia-reperfusion injury via the miR-1-GRP94 signaling pathway

Yanying Wang, Jian Huang, Han Sun, Jie Liu, Yingchun Shao, Manyu Gong, Xuewen Yang, Dongping Liu, Zhuo Wang, Haodong Li, Yanwei Zhang, Xiyang Zhang, Zhiyuan Du, Xiaoping Leng, Lei Jiao, Ying Zhang

Page range: 31-40

More Download PDF

Abstract

Objective Myocardial ischemia-reperfusion injury (MIRI) is one of the leading causes of death from cardiovascular disease in humans, especially in individuals exposed to cold environments. Long non-coding RNAs (lncRNAs) regulate MIRI through multiple mechanisms.This study explored the regulatory effect of lncRNA-AK138945 on myocardial ischemia-reperfusion injury and its mechanism. Methods In vivo , 8- to 12-weeks-old C57BL/6 male mice underwent ligation of the left anterior descending coronary artery for 50 minutes followed by reperfusion for 48 hours. In vitro , the primary cultured neonatal mouse ventricular cardiomyocytes (NMVCs) were treated with 100 μmol/L hydrogen peroxide (H 2 O 2 ). The knockdown of lncRNA-AK138945 was evaluated to detect cardiomyocyte apoptosis, and a glucose-regulated, endoplasmic reticulum stress-related protein 94 (GRP94) inhibitor was used to detect myocardial injury. Results We found that the expression level of lncRNA-AK138945 was reduced in MIRI mouse heart tissue and H 2 O 2 -treated cardiomyocytes. Moreover, the proportion of apoptosis in cardiomyocytes increased after lncRNA-AK138945 was silenced. The expression level of Bcl2 protein was decreased, and the expression level of Bad, Caspase 9 and Caspase 3 protein was increased. Our further study found that miR-1a-3p is a direct target of lncRNA-AK138945, after lncRNA-AK138945 was silenced in cardiomyocytes, the expression level of miR-1a-3p was increased while the expression level of its downstream protein GRP94 was decreased. Interestingly, treatment with a GRP94 inhibitor (PU-WS13) intensified H 2 O 2 -induced cardiomyocyte apoptosis. After overexpression of FOXO3, the expression levels of lncRNA-AK138945 and GRP94 were increased, while the expression levels of miR-1a-3p were decreased. Conclusion LncRNA-AK138945 inhibits GRP94 expression by regulating miR-1a-3p, leading to cardiomyocyte apoptosis. The transcription factor Forkhead Box Protein O3 (FOXO3) participates in cardiomyocyte apoptosis induced by endoplasmic reticulum stress through up-regulation of lncRNA-AK138945.

Open Access April 30, 2024

Notum protects against myocardial infarction-induced heart dysfunction by alleviating cardiac fibrosis

Tongzhu Jin, Zhen Ye, Ruonan Fang, Yue Li, Wei Su, Qianqian Wang, Tianyu Li, Hongli Shan, Yanjie Lu, Haihai Liang

Page range: 41-50

More Download PDF

Abstract

Background and Objective Cardiac fibrosis is a pathological reparative process that follows myocardial infarctionand is associated with compromised cardiac systolic and reduced cardiac compliance. The Wnt signaling pathway is closely implicated in organ fibrosis, and Notum, a highly conserved secreted inhibitor, modulates Wnt signaling. The objective of this study was to explore the role and mechanism of Notum in cardiac fibrosis. Methods A mouse model of cardiac remodeling was established through left coronary artery ligation surgery, with the addition of Notum injection following myocardial infarction surgery. The protective effect of Notum on myocardial infarction was assessed by evaluating cardiac function, including survival rate, echocardiographic assessment, and cardiac contraction analyses. Inflammatory cell necrosis and infiltration were confirmed through H&E and Masson staining. The expression of fibrosis-related genes and β-catenin pathway markers was detected using Western blot quantificational RT-PCR (qRT-PCR). Additionally, EdU, wound healing, and immunofluorescence staining analyses were performed to detect the effect of Notum’s in transforming growth factor beta-1 (TGF-β1) induced myofibroblast transformation. Results The administration of Notum treatment resulted in enhanced survival rates, improved cardiac function, and decreased necrosis and infiltration of inflammatory cells in mice subjected to left coronary artery ligation. Furthermore, Notum effectively impeded the senescence of cardiac fibroblasts and hindered their pathological transformation into cardiac fibroblasts. Additionally, it significantly reduced collagen production and attenuated the activation of the Wnt/β-catenin pathway. Our preliminary investigations successfully demonstrated the therapeutic potential of Notum in both fibroblasts in vitro and in a mouse model of myocardial infarction-induced cardiac fibrosis in vivo . Conclusion Notum inhibition of the Wnt/β-catenin signaling pathway and cardiac fibroblast senescence ultimately hampers the onset of cardiac fibrosis. Our findings suggest that Notum could represent a new therapeutic strategy for the treatment of cardiac fibrosis.

Open Access April 30, 2024

YBX1 inhibits mitochondrial-mediated apoptosis in ischemic heart through the PI3K/AKT signaling pathway

Fangfang Bi, Miao Cao, Yuquan Wang, Qingming Pan, Zehong Jing, Danyang Bing, Lifang Lyu, Tong Yu, Tianyu Li, Xuelian Li, Haihai Liang, Hongli Shan, Yuhong Zhou

Page range: 51-64

More Download PDF

Abstract

Background Myocardial infarction (MI) is associated with higher morbidity and mortality in the world, especially in cold weather. YBX1 is an RNA-binding protein that is required for pathological growth of cardiomyocyte by regulating cell growth and protein synthesis. But YBX1, as an individual RNA-binding protein, regulates cardiomyocytes through signaling cascades during myocardial infarction remain largely unexplored. Methods In vivo, the mouse MI model was induced by ligating the left anterior descending coronary artery (LAD), and randomly divided into sham operation group, MI group, MI+ YBX1 knockdown/overexpression group and MI+ negative control (NC) group. The protective effect of YBX1 was verified by echocardiography and triphenyltetrazolium chloride staining. In vitro, mitochondrial-dependent apoptosis was investigated by using CCK8, TUNEL staining, reactive oxygen species (ROS) staining and JC-1 staining in hypoxic neonatal mouse cardiomyocytes (NMCMs). Results YBX1 expression of cardiomyocytes was downregulated in a mouse model and a cellular model on the ischemic condition. Compared to mice induced by MI, YBX1 overexpression mediated by adeno-associated virus serotype 9 (AAV9) vector reduced the infarcted size and improved cardiac function. Knockdown of endogenous YBX1 by shRNA partially aggravated ischemia-induced cardiac dysfunction. In hypoxic cardiomyocytes, YBX1 overexpression decreased lactic dehydrogenase (LDH) release, increased cell viability, and inhibited apoptosis by affecting the expression of apoptosis related proteins, while knockdown of endogenous YBX1 by siRNA had the opposite effect. Overexpression of YBX1 restored mitochondrial dysfunction in hypoxic NMCMs by increasing mitochondrial membrane potential and ATP content and decreasing ROS. In hypoxic NMCMs, YBX1 overexpression increased the expression of phosphorylated phosphatidylinositol 3 kinase (PI3K)/AKT, and the antiapoptosis effect of YBX1 was eliminated t by LY294002, PI3K/AKT inhibitor. Conclusion YBX1 protected the heart from ischemic damage by inhibiting the mitochondrial-dependent apoptosis through PI3K/AKT pathway. It is anticipated that YBX1 may serve as a novel therapeutic target for MI.

Volume 4 (2024)

Issue 1

Volume 3 (2023)

Volume 2 (2022)

Volume 1 (2021)

No ranking information is available for this journal.

Submit

Please submit your manuscript at www.editorialmanager.com/fzm/, where you will be guided through the peer reviewing and submission process.

If you have any other question, please contact the Editorial Office at: fzm@frigidzonemedicine.com.

Your benefits of publishing with us

All articles published open access with a Creative Commons Attribution (CC BY 4.0) license without costs for the author.
High quality manuscript processing.
Every article easily discoverable because of SEO and comprehensive abstracting and indexing services.
Secure archiving by De Gruyter and the independent archiving service Portico.

Submission process

Please format your manuscript according to the Information for Authors and the Author statement
Manuscripts must be written in clear and concise English.
The journal operates a double-blind peer review process
The reviewing process takes on average two months. Submissions are sent to 2–3 reviewers. You will be informed by e-mail if your manuscript has been accepted or rejected or if it requires further attention. Every effort is made to respond to authors in a timely manner

Please note

Before submitting your article, please carefully read our Publication Ethics Statement.
All initial submissions are checked for plagiarism via Crossref Similarity Check.
If you have any general questions please visit our FAQ page for journal authors.

We look forward to receiving your manuscript!

Editorial

Editor-in-Chief

Baofeng Yang, Harbin Medical University, Harbin, China

Stanley Nattel, Montreal Heart Institute, Montreal, Canada

Deputy Editors-in-Chief

Ye Tian, Harbin Medical University, Harbin, China

Yong Zhang, Harbin Medical University, Harbin, China

Yongchen Wang, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

Yue Li, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Zhengwei Pan, Harbin Medical University, Harbin, China

Editorial Board Members

Andreas Papapetropoulos, National and Kapodistrian University of Athens, Athens, Greece

Bo Yu, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

Danfeng Yang, Institute of Environmental and Operation Medicine, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing, China

Deyou Jiang, Heilongjiang University of Chinese Medicine, Harbin, China

Edita Margaryan, Sechenov First Moscow State Medical University, Moscow, Russia

Gautam Sethi, Department of Pharmacology, National University of Singapore, Singapore City, Singapore

Irina Makeeva, Sechenov University, Moscow, Russia

Jianping Xu, Peking Union Medcial College Hospital, Beijing, China

Jinsong Bian, Southern University of Science and Technology, Shenzhen, China

Jinxin Bei, Sun Yat-sen University Cancer Center, Guangzhou, China

Jun Yu, Johns Hopkins University School of Medicine, Baltimore, US

Kun Huang, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Le Li, The University of Texas MD Anderson Cancer Center, Houston, US

Lei Yang, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Liangdan Sun, North China University of Science and Technology, Tangshan, China

Ling Yang, Shanghai Universty of Traditional Chinese Medicine, Shanghai, China

Lixia Yue, University of Connecticut School of Medicine, Farmington, US

Luwen Zhu, Heilongjiang University of Traditional Chinese Medicine, Harbin, China

Malov Igor, Irkutsk State Medical University, Irkutsk, Russia

Matthew Whiteman, University of Exeter Medical School, Exeter, UK

Rui Wang, York University, Toronto, Canada

Sergey Efetov, IM Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Wei Wang, Edith Cowan University, Perth, Australia

Weidong Zhang, Naval Medical University, Shanghai, China

Xi Yang, University of Manitoba, Winnipeg, Canada

Yue Yuan, Baylor College of Medicine, Houston, US

Zheng Liu, Cancer Hospital Chinese Academy of Medcial Sciences, Beijing, China

Managing Editor

Guodong Liu, Heilongjiang Health Development Research Center, Harbin, China

Yangang Ren, Peking University Health Science Center, Harbin, China

Editors

Xiaoxiao Wang, Heilongjiang Health Development Research Center, Harbin, China

Xize Wang, Heilongjiang Health Development Research Center, Harbin, China

Yue Yuan, Harbin Medical University, Harbin, China

(Deutsch)

Type: Journal
Language: English
Publisher: De Gruyter Open Access
First published: March 20, 2021
Publication Frequency: 4 Issues per Year